Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III Study Against COVID-19
Shots: The P-III trial evaluates REGEN-COV (1200mg, SC) vs PBO in a ratio (1:1) in patients who lived in the same household with COVID-19 patients diagnosed within the prior 4 days. The trial is jointly run with NIAID The results showed an 81.6% reduction in risk of COVID-19 during a pre-specified follow-up period b/w 2-8mos. […]